12:00 AM
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Diane 35 cyproterone/ethinylestradiol regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the benefits of Bayer's Diane 35 cyproterone/ethinylestradiol and its generic versions outweigh the risks, provided that measures are taken to minimize the risk of thromboembolism. PRAC said the medicines should only be used to treat moderate...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >